NCT01328054View on ClinicalTrials.gov

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Cancer
Interventions
DRUG

lapatinib

lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period

DRUG

placebo matching lapatinib

placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period

Trial Locations (4)

27710

GSK Investigational Site, Durham

48202

GSK Investigational Site, Detroit

84112

GSK Investigational Site, Salt Lake City

03756

GSK Investigational Site, Lebanon

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01328054 - A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval | Biotech Hunter | Biotech Hunter